What’s Going On With Vera Therapeutics Stock Today?
Vera Therapeutics' significant market movements! Discover the latest on atacicept in IgA nephropathy trials, analyst ratings, and FDA approvals.
Psychedelics Headlines: Anti-inflammatory Effects, Global Drug Survey, ‘Synthetic Surprise,’ UK’s Harm Reduction Hub And More
Discover the latest research on psychedelics, from anti-inflammatory effects to end-of-life therapy. New journal issue and online course available.
Benzinga’s ‘Stock Whisper’ Index: 5 Stocks Investors Secretly Monitor But Don’t Talk About Yet (Donald Trump Has Re-Entered The Chat)
The Benzinga Stock Whisper Index provides a look at five stocks that saw increased attention from traders over the past week.
What’s Going On With Anti Cancer Focused Processa Pharmaceuticals Stock Today?
Processa Pharmaceuticals stock surge - 148.8% gain to $5.10 post Next Generation Capecitabine (NGC-Cap) Phase 1b success.
What’s Going On With Panbela Therapeutics Stock?
Panbela Therapeutics has a float of only 480,324 shares after the company effected a 1-for-20 reverse split on Jan. 18. Heavy trading volume combined with the small float may be contributing to the stock's large move on Friday.
PTC Therapeutics To Withdraw Its Conditionally Approved Rare Muscle Disorder Disorder Drug In Europe
CHMP issues negative opinion on PTC Therapeutics' Translarna for Duchenne Muscular Dystrophy. CEO expresses disappointment.
Regeneron/Sanofi’s Largest Selling Drug Dupixent Scores FDA Approval For Infants With Esophagus Inflammation
FDA approves Dupixent (dupilumab) by Regeneron/Sanofi for pediatric eosinophilic esophagitis treatment. Breakthrough treatment for young patients.
What’s Going On With Prostate Cancer Focused ESSA Pharma Stock Today?
ESSA Pharma shares fell 22.6% at $6.80 yesterday. Explore masofaniten's promising Phase 1/2 results in prostate cancer treatment. Updated data, PSA reductions, and financial strength.
Vanda Pharmaceuticals Announces The U.S. Patent And Trademark Office Issued A Notice Of Allowance For PONVORY #17/962,968, Covering Methods For Reducing Clinical Management Events Before Or During The Treatment Of MS And Methods For Reinitiating Treatm…
Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced that the U.S.
Ultragenyx Announces Completion Of Dosing Across Stage 1 Cohorts In Pivotal Phase 1/2/3 Cyprus2+ Study Evaluating UX701 Gene Therapy For The Treatment Of Wilson Disease
Safety and initial efficacy data from Stage 1 expected in the first half of 2024 Dose selection and initiation of Stage 2 to follow in the second half of 2024NOVATO, Calif., Jan. 25, 2024 (GLOBE NEWSWIRE) --